Samsung Biologics Strike Enters Second Day as Wage Talks Stall

Introduction

Unionized workers at Samsung Biologics, the biotech arm of South Korea's Samsung Group, entered the second day of a five-day general strike on Saturday, marking the first labor walkout since the company was established in 2011. According to union officials, the strike began on Friday, with about 2,800 of the union's 4,000 members participating, as reported by Yonhap News Agency.

The labor dispute centers on wage increases and performance-based compensation. The union is demanding a 14 percent increase in both base and performance-related pay, a one-off cash incentive of 30 million won (approximately US$20,390) per worker, and bonuses equivalent to 20 percent of annual operating profit. The company has countered with a combined 6.2 percent increase in base and performance pay, according to multiple reports.

Coverage Comparison

All reports in this analysis come from Yonhap News Agency, South Korea's leading wire service, which has maintained a neutral tone throughout its coverage. The first-day reports detailed the strike's commencement and the company's potential losses, estimating that a full-scale strike could exceed 640 billion won (US$433 million) — roughly half of the company's first-quarter sales of 1.26 trillion won. A later update noted that the company estimated current losses at around 150 billion won due to halted production of anticancer drugs and HIV treatments.

A subsequent report on May 5 confirmed the strike continued for a fifth day and noted the union planned to shift to a work-to-rule campaign the following day. Another report placed the strike in the broader context of labor disputes spreading across major South Korean industries, mentioning simultaneous tensions at Kakao Corp.

While the core facts are consistent across all reports, some details vary. For instance, the participation figure of 2,800 workers appeared in only one report, while others did not specify membership numbers. Similarly, the company's current loss estimate of 150 billion won was reported in two articles but not all. These variations likely reflect the evolving nature of the situation rather than contradictions.

Key Claims

The strike marks the first collective labor action at Samsung Biologics since its founding in 2011, according to multiple reports.

The union is seeking a 14 percent increase in base and performance-related pay, alongside a one-off cash incentive and profit-linked bonuses, as reported consistently across all sources.

The company has proposed a combined 6.2 percent increase in base and performance pay, a figure that appears in every report.

Negotiations between the two sides have failed to bridge significant differences despite 13 rounds of talks held between December and March, per Yonhap's reporting.

Samsung Biologics estimated that losses from a full-scale strike could exceed 640 billion won, with current losses estimated at around 150 billion won, as reported by Yonhap.

The company filed for a court injunction to block the strike, but the court partially upheld it, restricting industrial action to three of nine production stages while allowing the remaining six to proceed. The company has appealed the ruling, according to Yonhap.

Perspectives

From the union's perspective, the strike is a necessary response to management's inadequate wage offer. Union officials have emphasized the need for a 14 percent increase and profit-sharing mechanisms, arguing that workers deserve a fair share of the company's success. The union's decision to move to a work-to-rule campaign after the five-day strike indicates a commitment to sustained pressure.

From the company's perspective, management has warned of irreversible losses and emphasized its commitment to dialogue. CEO John Rim urged employees to carefully consider participation, stating, "The company will continue sincere dialogue with the union to help stabilize labor-management relations and build a workplace based on mutual trust and respect." The company has also said it is taking all possible measures to minimize damage for clients.

Industry officials have highlighted the broader risks, noting that disruptions in biopharmaceutical manufacturing could affect product quality, given global regulators' emphasis on "process integrity" in production.

The labor dispute at Samsung Biologics is part of a wider trend in South Korea, as labor unions across major industries push for performance-based pay and profit-sharing, as seen in the simultaneous standoff at Kakao.